Anisha B. Patel, M.D.
Department of Dermatology, Division of Internal Medicine
Meet Anisha Patel, M.D.
Podcast: Sun safety advice for cancer survivors
In the News
Dermatologist: How to deal with targeted therapy-related skin rashes
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
Need a punch biopsy? Here’s what to expect
Cancer treatment-related nail changes: 7 things to know
10 sunscreen myths debunked
5 questions about laser tattoo removal, answered
Pregnancy-related skin changes or skin cancer? How to tell the difference
Present Title & Affiliation
Primary Appointment
Professor, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Deputy Chair, Department of Dermatology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Chief, Section of Cutaneous Toxicities, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Dermatology, The University of Texas Health Houston McGovern Medical School, Houston, TX
Education & Training
Degree-Granting Education
| 2008 | Baylor College of Medicine, Houston, Texas, US, MD |
| 2002 | Rice University, Houston, Texas, US, Mechanical Engineering and Materials Science, BS |
Postgraduate Training
| 2012-2013 | Clinical Fellowship, Dermatopathology, University of Texas-Medical Branch, Galveston, Texas |
| 2009-2012 | Clinical Residency, Dermatology, Oregon Health and Science University, Portland, Oregon |
| 2008-2009 | Intern, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2013 | American Board of Dermatology and Pathology for Sub-specialization in Dermatopathology |
| 2012 | American Board of Dermatology |
| 2012 | Texas Medical Board |
| 2011 | Oregon Medical Board |
| 2010 | Oregon Medical Board |
| 2009 | Oregon Medical Board |
| 2008 | Texas Medical Board Limited License |
| 2002 | Texas Society of Professional Engineers -Engineer in Training |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025
Assistant Professor, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Clinical Instructor, Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, 2012 - 2013
Other Professional Positions
Chief Resident, Oregon Health and Science-Department of Dermatology, Portland, OR, 2011 - 2012
Engineer, Lyondell Chemical Company, Houston, TX and Rotterdam, Netherlands, Houston, TX, 2002 - 2004
Extramural Institutional Committee Activities
Chair, Dermatopathology Commitee, American Academy of Dermatology | Association (AAD/A) 2026 Committee Appointment, 2026 - 2028
EX-Officio, Council on Government Affairs and Health Policy, American Academy of Dermatology | Association (AAD/A) 2026 Committee Appointment, 2026 - 2028
Member, Dermatology Chair Search Committee, University of Texas McGovern Medical School, 2025 - Present
Co-Chair, Institutional Committee, IoTox Leaders Group, The University of Texas MD Anderson Cancer Center, 2025 - Present
Scientific Lead, Immunotherapy Toxicity Operational Platform (ITOP), The University of Texas MD Anderson Cancer Center, 2024 - Present
Chair, Dermatology Research Review Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Dermatology Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Divisional Representative, PRS Faculty Compensation & Benefit Advisory Committee, Divisional Representative, The University of Texas MD Anderson Cancer Center, 2023 - Present
Chair, Division of Internal Medicine Grand Rounds Steering Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Advisory Council of Clinical Research Leaders (ACCRL), The University of Texas MD Anderson Cancer Center, 2022 - Present
Networking Chair, Mid-Career Faculty Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2024
Vice Chair, Dermatology Research Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2024
Member, Faculty Vitality and Engagement Council, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, Mid-Career Faculty Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, Leadership group, Institutional Immunotherapy Toxicity Initiative, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Executive Committee, Institutional Immunotherapy Toxicity Initiative, The University of Texas MD Anderson Cancer Center, 2019 - Present
Deputy Chair, Division of Internal Medicine Grand Rounds Steering Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2023
Co-Chair, DoIM Denials Prevention Task Force, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, Denials Prevention Task Force, The University of Texas MD Anderson Cancer Center, 2018 - 2019
Member, Operational Priority for Financial Sustainability, The University of Texas MD Anderson Cancer Center, 2017 - 2019
Member, Faculty Health and Well Being, The University of Texas MD Anderson Cancer Center, 2016 - 2018
Chair, Junior Faculty Committee, Peer Networking Working Group, The University of Texas MD Anderson Cancer Center, 2016 - 2019
Member, Steering Committee, Div of Internal Med Grand Rounds, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, Steering Committee, Focus on Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2019
Member, Faculty Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2017
Participant, Heart of Leadership Program, The University of Texas MD Anderson Cancer Center, 2014 - 2015
Reviewer, Institutional Protocols, The University of Texas MD Anderson Cancer Center, 2013 - Present
Editorial Activities
Member of Editorial Review Board, Journal of Cutaneous Pathology, 2020 - Present
Member of Editorial Review Board, Journal of American Academy of Dermatology, 2018 - Present
Member of Editorial Review Board, Practical Dermatology, 2018 - Present
Honors & Awards
| 2026 | Top 1% Patient Experience Recognition Event, UT MD Anderson Cancer Center |
| 2026 | Top 10% Patient Experience Recognition Event, UT MD Anderson Cancer Center |
| 2024 | Top 10% Nationally: Clinician and Group Consumer Assessment of Healthcare Providers and Systems 2024 |
| 2023 | American Academy of Dermatology’s Presidential Citation |
| 2023 | Fiscal Year 2023: Top 1% Providers Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) |
| 2023 | Advanced Dermatology Leadership Forum Participant, American Academy of Dermatology |
| 2023 - 2024 | Leading Others Core Curriculum, MD Anderson Leadership Institute |
| 2022 - 2024 | Graduate, Faculty Academic Career Development Academy |
| 2022 | Fiscal Year 2022: Top 1% Providers Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) |
| 2021 | Patient Care Hero, American Academy of Dermatology |
| 2019 | Mentorship Award (Mentor), Women's Dermatologic Society |
| 2018 | Top 10% Nationally: Clinician and Group Consumer Assessment of Healthcare Providers and Systems 2018 |
| 2018 | Executive-decision making workshop, Center for Entrepreneurship Advancement, Houston, TX Nov 2018 |
| 2017 | Faculty Educator of the Month of May 2017, UT MD Anderson Cancer Center |
| 2016 | Academic Dermatology Leadership program, American Academy of Dermatology |
| 2016 | Leadership Forum, American Academy of Dermatology |
| 2011 | Mentorship Travel Award (Mentee), Women's Dermatologic Society |
| 2008 - 2024 | Alpha Omega Alpha Honors Society |
| 2008 - 2024 | Gold Humanism Honors Society |
| 2008 | John P. McGovern, M.D. Award for Excellence in Psychiatry, Baylor College of Medicine |
| 2005 - 2006 | Honorable Mention, Richard Epp right Award for Excellence in Orthopedic Research, Baylor College of Medicine |
| 2002 | Alan J Chapman Award for Outstanding Performance in Mechanical Engineering |
| 2002 | Athenian Award for Service, Rice University |
| 2002 | Phi Beta Kappa Honors Society |
| 2002 | Tau Beta Pi Engineering Honors Society |
| 2002 | Young Engineer of the Year, Texas Society of Professional Engineers |
| 2000 - 2001 | Lon Wilson Service Award, Sid Richardson College, Rice University |
| 1998 - 2008 | Rice University/Baylor College of Medicine Medical Scholar, Baylor College of Medicine and Rice University |
| 1998 - 2002 | Louis J. Walsh Engineering Scholar, Rice University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Clinical Challenges and Research Innovations in irAEs I. Invited. 2026 MD Anderson IOTOX Symposium. Houston, Texas, US.
- 2025. Immune-related Dermatitis. Conference. FY25 IOTOX Research Series. Houston, Texas, US.
- 2025. Cutaneous Toxicities to Immunotherapy. Conference. FY25 IOTOX Educational Series. Houston, Texas, US.
- 2024. Immunotherapy-Induced Dermatologic Toxicities. Conference. APRN LEAP-N Lecture Series. Houston, US.
- 2023. Algorithmic management of acneiform eruptions. Conference. Grand Rounds. Houston, TX, US.
- 2023. Skin Cancer in Skin of Color. Invited. Black History Month Event. Houston, Texas, US.
- 2022. Management of Cutaneous Toxicities. Invited. Immunotherapy Toxicity Clinical Symposium. Houston, TX, US.
- 2022. Updates to clinical management of cutaneous IOTOX,. Conference. FY23 IOTOX educational program series, US.
- 2022. Dermatological Side Effects from Breast Cancer Treatment. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
- 2022. Updates to Cutaneous Toxicities in Targeted and Immune Therapies. Conference. Grand Rounds. Houston, TX, US.
- 2022. Dermatologic Complications of Immunotherapy. Conference. IO Toxicity Lecture Series. Houston, TX, US.
- 2021. Cutaneous Toxicities in Cancer Therapy. Conference. Toxicities Lecture Series. Houston, TX, US.
- 2021. Cutaneous Toxicities in Cancer Therapy. Conference. Toxicities Lecture Series, Clinical and Research Conference. Houston, Texas, US.
- 2021. Cutaneous Toxicities. Conference. IOTOX Guideline Lecture Series. Houston, TX, US.
- 2021. Updates in Cutaneous Toxicities to Immune Checkpoint Inhibitors. Conference. Grand Rounds. Houston, TX, US.
- 2021. Cutaneous Toxicities: The MD Anderson Experience. Conference. Grand Rounds. Houston, TX, US.
- 2019. Managing the Metastatic Melanoma Patient: Toxicities to Targeted and Immune Therapies. Conference. Texas Dermatology Society. Houston, TX, US.
- 2018. Dermatologic toxicities seen in cancer therapy: Focus on targeted and immunotherapy. Conference. Research Seminar series. Houston, TX, US.
- 2018. Inflammatory rashes in cancer patients. Conference. Clinical and Research Conference. Houston, TX, US.
- 2017. Cutaneous adverse events to small molecule and immune checkpoint inhibitors. Conference. Grand Rounds. Houston, TX, US.
- 2017. Update on cutaneous reactions to targeted and immune cancer therapy. Conference. Grand Rounds. Houston, TX, US.
- 2016. Cutaneous reactions as prognostic indicators in the treatment of metastatic melanoma. Invited. Knox Lectureship. Houston, TX, US.
- 2016. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Conference. Teaching Video Series. Houston, TX, US.
- 2016. Skin complications of cancer therapy. Conference. PIKNIC lectureship series. Houston, TX, US.
- 2016. Cutaneous Reactions of Targeted Drug Therapy. Conference. Houston Dermatological Society. Houston, TX, US.
- 2016. Cutaneous drug reactions of novel therapeutics. Conference. Grand Rounds. Houston, TX, US.
- 2015. Dermatologic Lesions: Diagnosis and Management. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
- 2014. Cutaneous drug reactions of novel therapeutics. Conference. Grand Rounds. Houston, TX, US.
Regional Presentations
- 2026. Onchodermatology. Invited. Texas Dermatological Society (TDS) Fall 2026 Conference. San Antonio, Texas, US.
- 2026. Cutaneous Toxicities of Skin Cancer. Invited. 18th Annual UNC Melanoma and Complex skin Cancer Conference. Chapel Hill, North Carolina, US.
- 2026. Management of Common Skin-Related Side Effects During and After Cancer Treatment. Invited. Scripps Clinical Hematology & Oncology Conference 2026. San Diego, California, US.
- 2025. Medical Therapeutics in Dermatology. Invited. PDA-PDS Spring Training. Scottsdale, Arizona, US.
- 2025. Charting a Path: An Algorithmic Approach to Diagnosis and Management of Cutaneous Toxicities of Immunotherapy. Conference. 7th Annual Melanoma Symposium. Scottsdale, Arizona, US.
- 2024. Cutaneous toxicities to inhibition of the MAP kinase pathway. Visiting. Dowling Club Visiting Professorship. Irvine, CA, US.
- 2024. Charting a Path: An Algorithmic Approach to Cutaneous Toxicities to Cancer Therapy. Invited. Annual Meeting. Philadelphia, PA, US.
- 2024. Update on cutaneous toxicities to cancer therapy. Visiting. Department of Dermatology Grand Rounds. Lebanon, NH, US.
- 2023. Medical management of pigmentary disorders. Conference. Texas Dermatologic Society Fall Meeting. San Antonio, TX, US.
- 2023. Cutaneous manifestations of cancer therapy. Conference. Texas Dermatologic Society Fall Meeting. San Antonio, TX, US.
- 2022. Increasing knowledge, awareness, and protective behaviors for skin students of color. Conference. Nevada Cancer Coalition Cancer Prevention Task Force. Las Vegas, NV, US.
- 2019. Managing the Metastatic Melanoma Patient. Conference. Dallas/Ft Worth Dermatology Society. Fort Worth, TX, US.
- 2017. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Invited. Oncology Summit. Portland, OR, US.
- 2017. Toxicity from Targeted Therapy. Invited. Annual Meeting. Houston, TX, US.
- 2017. Toxicity from Immune Targeted Therapy. Invited. Annual Meeting. Houston, US.
- 2017. Oncodermatology: interesting cases and pearls. Invited. Annual meeting. Big Sky, MT, US.
- 2017. Update in pigmentary disorders: from Vitiligo to PIH. Invited. Annual meeting. Big Sky, MT, US.
- 2017. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Invited. Annual meeting. Big Sky, MT, US.
- 2016. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Invited. Oncology Summit. Portland, OR, US.
- 2016. Update in Pigmentary Disorders: from Vitiligo to PIH. Invited. Summer Meeting. Sunriver, OR, US.
- 2016. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Invited. Summer meeting. Sunriver, OR, US.
- 2014. Grand Rounds: Dermatopathology unknowns. Conference. UT Medical Branch. Galveston, TX, US.
- 2014. Grand Rounds: Post inflammatory hyperpigmentation & pigmentary disorders. Conference. UT Medical Branch. Galveston, TX, US.
- 2014. Grand Rounds: Post inflammatory hyperpigmentation & periorbital hyperpigmentation. Conference. Oregon Health & Science University. Portland, OR, US.
- 2011. Expanding ulcers: Pyoderma gangrenosum or infection?. Conference. Monthly meeting. Portland, OR, US.
- 2011. The hex of Bazex: The importance of persistent evaluation in atypical psoriasis. Invited. Annual Meeting. Cour d'Alene, ID, US.
- 2011. Tyrosine Kinase Inhibitors in Dermatology. Invited. Annual Meeting. Vancouver, British Columbia, CA.
- 2010. The diagnosis is in the DIF. Conference. Monthly meeting. Portland, OR, US.
- 2009. A pustular eruption in an adult: a case of acute generalized exanthematous pustulosis. Conference. Monthly meeting. Portland, OR, US.
National Presentations
- 2026. Dermatological Toxicities. Invited. 22nd Oncology Updates: Advances and Controversies. Steamboat Springs, Colorado, US.
- 2025. Complex Medical Dermatology: Top Diagnoses You Can't Afford to Miss. Conference. Elevate Dermatology Conference. Park City, Utah, US.
- 2025. Immunotherapy in Dermatology: Innovations & Clinical Applications. Conference. Elevate Dermatology Conference. Park City, Utah, US.
- 2025. Skin as a Window: Identifying Cancer Syndromes Through Cutaneous Clues. Conference. Elevate Dermatology Conference. Park City, Utah, US.
- 2025. A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies. Invited. AACR Annual Meeting 2025. Chicago, Illinois, US.
- 2025. Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy. Invited. 2025 AAD Annual Meeting. Orlando, Florida, US.
- 2025. What's New in Dermatopathology. Invited. 2025 AAD Annual Meeting. Orlando, Florida, US.
- 2025. Dermatological Toxicities. Invited. 21st Oncology Updates: Advances and Controversies. Houston, Texas, US.
- 2024. Granulomatous secondary syphilis with peri eccrine involvement: an atypical histological presentation. Poster. American Society of Dermatopathology Annual Meeting. Chicago, Illinois, US.
- 2024. Medical management of facial hyperpigmentation. Invited. Charleston, SC, US.
- 2024. Cemiplimab use in advanced cutaneous squamous cell carcinoma and non-small cell lung cancer. Poster. Annual Meeting. Orlando, FL, US.
- 2024. Updates on Cutaneous Reactions to Targeted and Immune Cancer Therapy. Invited. Annual Meeting. San Diego, CA, US.
- 2024. Histopathologic approach to infections in the leukemia and lymphoma patient. Invited. Annual Meeting. San Diego, CA, US.
- 2024. What's new in pigmentary disorder histopathology?. Invited. Annual Meeting. San Diego, CA, US.
- 2024. Dermatologic Toxicities. Invited. 20th Oncology Updates: Advances and Controversies. Steamboat Springs, CO, US.
- 2023. Updates on Cutaneous Reactions to Targeted and Immune Cancer Therapy. Invited. Annual Meeting. New Orleans, LA, US.
- 2023. Cutaneous Reactions in Cancer Therapies: What's New in Dermatopathology. Invited. Annual Meeting. New Orleans, LA, US.
- 2023. Skin Biopsies in the Leukemia and Lymphoma Patient: Limits and Advantages. Invited. Annual Meeting. New Orleans, LA, US.
- 2023. Updates in Cutaneous Toxicities to Cancer Therapy. Invited. 45th Annual Hawaii Dermatology Seminar. Honolulu, HI, US.
- 2023. Cutaneous Manifestations of Immune-related Adverse Events. Invited. Annual Meeting, US.
- 2022. Work/life balance and preventing burnout. Invited. Virtual Career Launch Bootcamp session, US.
- 2022. Cutaneous Toxicities to metastatic CRC therapy. Invited. Bayer/MDACC CRC Clinical Education Program. Houston, TX, US.
- 2022. Dermatologic Care for the Leukemia and Lymphoma patient. Invited. Annual Meeting. Boston, MA, US.
- 2022. Cutaneous Reactions in Cancer Therapies: What's New in Dermatopathology?. Invited. Annual Meeting. Boston, MA, US.
- 2022. Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy. Invited. Annual Meeting. Boston, MA, US.
- 2022. Checkpoint-Inhibitor Induced Vitiligo in Non-Melanoma Patients. Poster. Annual Meeting. Boston, MA, US.
- 2022. A Retrospective Chart Review of Management Strategies for Lichenoid Eruption Associated with Immune-Checkpoint Inhibitor Therapy from a Single Institution. Poster. Annual Meeting. Boston, MA, US.
- 2022. Caring for the Cancer Patient: Challenging Cases from Inpatient and Outpatient Oncodermatology Consultative Services. Invited. Annual Meeting. Boston, MA, US.
- 2021. Managing Skin Diseases in the Cancer Patient. Invited. VMX virtual, US.
- 2021. Cutaneous Surgery Outcomes in Patients on EGFR Inhibitor. Poster. American Academy of Dermatology, US.
- 2020. Hot Topics: Dermatopathology Fellowship. Invited. Chief Academy Virtual Hot Topics, US.
- 2020. Retrospective Chart Review of Cutaneous Adverse Events Associated with Pi3K Inhibitors in 15 Patients. Poster. Annual Meeting. Denver, CO, US.
- 2020. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy. Poster. Annual Meeting. Denver, CO, US.
- 2019. Histopathologic Comparison of Chondrodermatitis Nodularis Helicis and Hyperplastic Actinic Keratosis. Poster. Annual Meeting. Denver, CO, US.
- 2019. Cutaneous Side Effects of Targeted Cancer Therapies: Diagnosis and Management. Invited. Summer Meeting. New York, NY, US.
- 2019. Systemic Therapies for Medical Oncology. Invited. Summer Meeting. New York, NY, US.
- 2019. Update on cutaneous reactions to targeted and immune cancer therapy. Invited. Annual Meeting. Washington, DC, US.
- 2019. Twelve cases of acneiform eruption on anti-CTLA4 therapy. Poster. Annual Meeting. Washington, DC, US.
- 2019. Cutaneous toxicities in combination immune checkpoint inhibitor therapy for metastatic melanoma: impact on therapy. Poster. Annual Meeting. Washington, DC, US.
- 2019. Managing metastatic melanoma: Cutaneous toxicities to systemic therapies. Invited. Annual Meeting. Washington, DC, US.
- 2018. Development of cutaneous squamous cell carcinoma in patients receiving anti PD-1/PD-L1 therapy. Poster. Annual Meeting. Washington, DC, US.
- 2018. Difficult cases in cutaneous reactions to targeted and immune cancer therapy. Invited. Summer Meeting. Chicago, IL, US.
- 2018. Systemic therapies in medical oncology. Invited. Summer Meeting. Chicago, IL, US.
- 2018. Update on cutaneous reactions to targeted and immune cancer therapy. Invited. Annual Meeting. San Diego, CA, US.
- 2016. Clinicopathologic correlation in skin cancer treatment. Invited. Annual Meeting. New Orleans, LA, US.
- 2016. Case presentations. Invited. Self-assessment session. Chicago, IL, US.
- 2016. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Teaching Video Series. Invited. MD Anderson Physicians Network. Houston, TX, US.
- 2016. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Invited. Summer meeting. Boston, MA, US.
- 2015. Histopathology in Pigmentary Disorders, Short Course IV. Invited. Annual meeting. San Francisco, CA, US.
- 2015. Skin complications of cancer therapy. Conference. Survivorship Conference. Houston, TX, US.
- 2015. Cutaneous Reactions of Targeted Drug Therapy: Diagnosis and Management. Invited. Summer meeting. New York, NY, US.
- 2015. Skin Complications of Cancer Therapy. Invited. 3rd Conference on Medical Issues in Cancer Patients and Survivors. Houston, TX, US.
- 2011. Disseminated superficial porokeratosis heralding the onset of rheumatoid arthritis: A rare variant of disseminated superficial actinic porokeratosis with a unique presentation. Conference. Gross and Microscopic Symposium, Annual Meeting. New Orleans, LA, US.
International Presentations
- 2025. Multidisciplinary Consensus Recommendations on Proactive Management of Dermatologic Reactions Associated with Egfr-targeted Treatments for Lung Cancer. Conference. Multinational Association of Supportive Care in Cancer. Seattle, US.
- 2024. Charting a Path: The Algorithmic Approach to Checkpoint Inhibitor Induced Cutaneous Toxicities. Invited. Annual Meeting. Nagoya, JP.
- 2024. Cutaneous Toxicities to Cancer Therapies Advancing Science and Care of Patients and Survivors. Invited. Annual Meeting. Nagoya, JP.
- 2024. Dermatological approach to patients with cancer- the value of a multidisciplinary approach. Invited. Annual Meeting. Nagoya, JP.
- 2021. Dermatopathological review of Cutaneous Squamous Cell Carcinoma Events in Patients with Gastrointestinal Stromal Tumors Treated with Ripretinib. Poster. Annual Meeting, US.
- 2021. A Phase I Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients. Poster. Annual Meeting, US.
- 2020. Incidence, Characteristics, and Management of Alpelisib-Associated Rash in Patients with Advanced Breast Cancer. Poster. The Fall Clinical Dermatology Conference, US.
- 2019. Histopathologic Comparison of Cutaneous Adverse Events in Immune Checkpoint Blockade Therapy. Conference. 22nd Joint Meeting. Arlington, US.
- 2018. Cutaneous toxicities in immune checkpoint inhibitor therapy: features, management, and outcomes. Poster. Annual Meeting. Manchester.
- 2018. Cutaneous toxicities with anti PD-1 monotherapy: incidence, management, and outcomes in the real-world setting. Poster. Annual Meeting. Manchester.
- 2016. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Invited. Asian Dermatologic Congress. Mumbai, IN.
- 2012. Cutaneous side effects of 2nd and 3rd-generation tyrosine kinase inhibitors: Case series and review. Invited. International Society of Dermatopathology Pre-AAD meeting. San Diego, US.
- 2011. Mentorship in Dermatology. Invited. Women's Dermatologic Society Annual meeting. New Delhi, IN.
- 2011. Common variable immunodeficiency (CVID) presenting as a herpetic ulcer and disseminated zoster. Invited. International Society of Dermatopathology Pre-AAD meeting. New Orleans, US.
Formal Peers
- 2026. Dermatopathology Weekly Series. Houston, Texas, US.
- 2026. Dermatopathology Weekly Series. Houston, Texas, US.
- 2026. Dermatopathology Weekly Series. Houston, Texas, US.
- 2025. Ackerman Algorithm 2 part series. Houston, Texas, US.
- 2025. Diagnosis and management of facial hyperpigmentation. Houston, Texas, US.
- 2025. Cutaneous toxicities to cancer therapy: 2 part series. Houston, Texas, US.
- 2025. Managing Patient Call Backs and Messages. Houston, Texas, US.
- 2024. Cutaneous toxicities to cancer therapy: 2 part series. Houston, Texas, US.
- 2024. Ackerman Algorithm: 2 part series. Houston, Texas, US.
- 2024. Managing Patient Call Backs. Invited. Houston, TX, US.
- 2024. Skin Cancer in Skin of Color, UT Health Science Center. Invited. Houston, TX, US.
- 2024. Pigmentary Disorders: Advanced Management. Invited. Houston, TX, US.
- 2024. Cutaneous Toxicities to Targeted and Immune Therapy. Invited. Houston, TX, US.
- 2024. Dermatopathology Weekly Lecture Series. Invited. Houston, TX, US.
- 2023. Guest Dermatopathologist. Visiting. New Orleans, LA, US.
- 2023. Ackerman Algorithm in Dermatology. Invited. Houston, TX, US.
- 2023. Cutaneous side effects to targeted and immune therapies: diagnosis and management, Grand Rounds Lecturer. Visiting. Omaha, NE, US.
- 2023. Managing Patient Call Backs and Messages. Invited. Houston, TX, US.
- 2023. Medical Management of Pigmentary Disorders. Invited. Houston, TX, US.
- 2023. Dermatopathology Weekly Lecture Series,. Invited. Houston, TX, US.
- 2022. Cutaneous Toxicities to Targeted and Immune Therapy. Invited. Houston, TX, US.
- 2022. Ackerman Algorithm in Dermatology. Invited. Houston, TX, US.
- 2022. Dermatopathology Weekly Lecture Series. Invited. Houston, TX, US.
- 2021. Cutaneous Toxicities to Targeted and Immune Therapy. Invited. Houston, TX, US.
- 2021. Ackerman Algorithm in Dermatology. Invited. Houston, TX, US.
- 2021. Dermatopathology weekly lecture series. Invited. Houston, TX, US.
- 2020. Introduction to Dermatopathology, MS4 Lecture Series. Invited. Houston, TX, US.
- 2020. Dermatopathology weekly lecture series. Invited. Houston, TX, US.
- 2019. Dermatopathology weekly lecture series. Invited. Houston, TX, US.
- 2018. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Visiting. Detroit, MI, US.
- 2018. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Visiting. Gainesville, FL, US.
- 2018. Dermatopathology weekly lecture series. Invited. Houston, TX, US.
- 2017. Cutaneous side effects to targeted and immune therapies: diagnosis and management. Visiting. Philadelphia, PA, US.
- 2017. Dermatopathology weekly lecture series. Invited. Houston, TX, US.
- 2016. Dermatopathology weekly lecture series. Invited. Houston, TX, US.
- 2015. Dermatopathology Board Review Course. Invited. Galveston, TX, US.
- 2015. Dermatopathology weekly lecture series. Invited. Houston, TX, US.
- 2014. Resident Lecture Series: Melanoma: Staging, pathways, treatment, and review of cutaneous side effects of treatment. Invited. Houston, TX, US.
- 2014. Resident Lecture Series: Melanoma: Staging, pathways, and treatment. Invited. Houston, TX, US.
- 2014. Resident Lecture Series: Cutaneous effects of targeted therapies. Invited. Galveston, TX, US.
- 2014. Resident Lecture Series: Dermatology kodachromes. Invited. Houston, TX, US.
- 2014. Pigmentary Disorders. Visiting. Houston, TX, US.
- 2014. Grand Rounds: Pigmentary Disorders. Invited. Houston, TX, US.
- 2014. Cutaneous Toxicities to Cancer Therapy. Visiting. Houston, TX, US.
- 2014. Biology of Melanocytes. Visiting. Houston, TX, US.
- 2014. Dermatopathology weekly lecture series. Invited. Houston, TX, US.
- 2012. Do patients with methicillin-resistant staphyloccus aureus (MRSA) infections of the skin revert to methicillin-susceptible isolates?. Invited. Portland, OR, US.
- 2012. Acquired Pigmentary Disorders: Cases from the subcontinent. Invited. Portland, OR, US.
- 2011. Tyrosine kinase inhibitors in dermatology. Invited. Portland, OR, US.
- 2010. Immunomodulatory therapy in metastatic melanoma. Invited. Portland, OR, US.
- 2010. Novel treatment in staphylococcus aureus colonization. Invited. Portland, OR, US.
- 2010. MRSA in dermatology update. Invited. Portland, OR, US.
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | Digital photography and digital methodology in topical fluorouracil plus calcipotriene for treatment of actinic keratosis: a pilot trial |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2024 - 2028 |
| Title: | Immunotherapy Toxicity Operational Platform (ITOP), STRIDE Initiative |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | Scientific Chair |
| Date: | 2023 - 2025 |
| Title: | Evaluation of cutaneous immune related adverse events by morphotype |
| Funding Source: | Melanoma Research Foundation |
| Role: | Co-Investigator/Mentor |
| Date: | 2023 - 2025 |
| Title: | Topical fluorouracil plus calcipotriene for treatment of actinic keratosis: a pilot trial |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | Co-Investigator/Mentor |
| Date: | 2023 - 2026 |
| Title: | Quantifying Temporal Immunologic Changes with Hypo-fractionated Radiation-Induced DNA Damage in Breast Cancer |
| Funding Source: | Artidis Alliance |
| Role: | Co-I |
| Date: | 2016 - 2018 |
| Title: | National Alopecia Areata Registry |
| Funding Source: | Alopecia Areata Foundation |
| Role: | PI |
| Date: | 2011 - 2012 |
| Title: | Analysis of OHSU MRSA database to identify and quantify cases of MRSA positive patients who revert to MSSA |
| Funding Source: | Oregon Health And Science University, Dept. of Dermatology |
| Role: | PI |
| Date: | 2005 - 2006 |
| Title: | Computer model analysis system |
| Funding Source: | Baylor College of Medicine |
| Role: | Researcher |
| Date: | 1997 |
| Title: | New method of plutonium detection in nuclear geochemistry |
| Funding Source: | National Science Foundation (NSF) |
| Role: | Researcher |
Selected Publications
Peer-Reviewed Articles
- Patel AB. Postoperative outcomes in dermatologic surgery among patients receiving VEGF and VEGFR inhibitors: A propensity-matched real-world analysis. Dermatologic Surgery. e-Pub 2025.
- Papp Kim, Puig Luis, Beecker Jennifer, Chandran Vinod, Claveau Joel, Cortes Javier, Dutz Jan, Hornick Noah I, Juergens Rosalyn A, Melosky Barbara, Sauder Maxwell, Sehdev Sandeep, Sibaud Vincent, Patel Anisha B, Stephanie L. Systemic Treatment of Immune Checkpoint Inhibitor Induced Psoriasis: Inference-Based Guidance. J Eur Acad Dermatol Venereol 39(11):1881-1894, 2025. e-Pub 2025. PMID: 40685883.
- Pacha O, Patel AB, Curry JL, Haymaker CL, Lermi NO, Duose DY, Chen K, Hajjar J, Naing A. Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors. J Immunother Cancer 13(8), 2025. e-Pub 2025. PMID: 40780859.
- Burningham KM, Taha Mohamad, Cho SW, Alkul M, Patel AB, Tyring SK. Cutaneous lupus erythematosus presenting as a nonhealing ulcer in an African American woman. Am J Clin Pathol 164(2):154-156, 2025. e-Pub 2025. PMID: 40071946.
- Lee KP, Tsimberidou AM, Chakraborty A, Patel AB. Cutaneous toxicities secondary to STAT3 inhibition: A retrospective case series. JAAD Case Rep 61:136-142, 2025. e-Pub 2025. PMID: 40606688.
- Kale IP, McCauley EM, Patel AB. Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy. Supportive Care in Cancer 33(6):524, 2025. e-Pub 2025. PMID: 40455297.
- Moussa, MJ, Wilson, NR, Ghosh, A, Bhattacharjee, M, Curry, JL, Cho, WC, Patel, A, Habra, MA, Thosani, S, Campbell, M, Siefker-Radtke, AO, Alhalabi, O, Kikani, NJ. Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin. Annals of Internal Medicine Clinical Cases 4(5), 2025. e-Pub 2025.
- Apalla, Z, Freites-Martinez, A, Grafanaki, K, Ortiz-Brugues, A, Nikolaou, V, Fattore, D, Sollena, P, Deverapalli, S, Babakoohi, S, Galimont, A, Kluger, N, Beylot-Barry, M, Larocca, C, Iriarte, C, Smith, J, Tattersall, IW, Dodiuk-Gad, R, Sauder, M, Carrera, C, Kwong, BY, Whitley, MJ, LeBoeuf, NR, Romano, P, Starace, M, Mateeva, V, Riganti, J, Hirner, J, Patel, A, Reyes-Habito, CM, Kraehenbuehl, L, Kheterpal, M, Fida, M, Hassel, JC, Lacouture, ME, Sibaud, V. Management of human epidermal growth factor receptor inhibitors-related acneiform rash. Journal of the European Academy of Dermatology and Venereology 39(4):730-741, 2025. e-Pub 2025. PMID: 39460590.
- Muhaj FF, Tran J, Dai J, Pacha O, Patel AB. A retrospective case series of eight patients with epidermal growth factor receptor inhibitor-induced cutaneous toxicities managed with dupilumab. JAAD Case Rep 54:17-22, 2024. e-Pub 2024. PMID: 39583056.
- Friske S, Verma KK, Farooq S, Nguyen QB, Patel AB. Cutaneous Surgery Outcomes in Patients on Vascular Endothelial Growth Factor Receptor Inhibitors. Dermatol Surg, 2024. e-Pub 2024. PMID: 39361496.
- Tripathy S, Warbasse E, Ronen S, Al-Rohil R, Cohen GF, Chen WS, Patel AB. Clinicopathologic correlation of dermatologic diseases in patients with darker pigmentation. Am J Clin Pathol 162(2):115-140, 2024. e-Pub 2024. PMID: 38513285.
- Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw 22(5), 2024. e-Pub 2024. PMID: 38190801.
- Peacock BC, Tripathy S, Hanania HL, Wang HY, Sadighi Z, Patel AB. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1. J Neurooncol 167(3):515-522, 2024. e-Pub 2024. PMID: 38443692.
- Musicante M, Harrell JM, Kubicki S, Curry JL, Patel AB. When leukaemia masquerades: the hidden syphilis diagnosis. Lancet Oncol 25(5):e225, 2024. e-Pub 2024. PMID: 38697168.
- Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L, Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB, Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunn J, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M, Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy. J Immunother Cancer 12(4), 2024. e-Pub 2024. PMID: 38599660.
- Burningham KM, Verma KK, Patel AB, Tyring SK. Resolution of metastatic cutaneous Crohn's disease with upadacitinib monotherapy. JAAD Case Rep 46:81-84, 2024. e-Pub 2024. PMID: 38577495.
- Burningham KM, Swali RN, Rady PL, Patel AB, Tyring SK. Resolution of painful trichodysplasia spinulosa with topical cidofovir: case report. J Dermatolog Treat 35(1):2328180, 2024. e-Pub 2024. PMID: 38493799.
- Adjei S, Taha MR, Patel AB, Tyring SK. Atypical presentation of psoriasis on the breast of an elderly woman: A case report. SAGE Open Med Case Rep 12:2050313X241298884, 2024. e-Pub 2024. PMID: 39524494.
- Augustyn K, Joseph J, Patel AB, Razmandi A, Ali AN, Tawbi HA. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice. Melanoma Res 33(5):406-416, 2023. e-Pub 2023. PMID: 37534686.
- Lo J, Hanania HL, Keiser MF, Patel AB. Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management. Arch Dermatol Res 315(6):1697-1703, 2023. e-Pub 2023. PMID: 36809408.
- Vanden Heuvel J, Shou S, Patel AB, Kamerow H, Baran P, Ford J. Preclinical Demonstration of a Novel Treatment with High Efficacy and No Detectable Toxicity for Inflammatory Skin Conditions including Psoriasis. BioMed research international 2023, 2023. e-Pub 2023. PMID: 37469991.
- Marques-Piubelli ML, Seervai RNH, Mudaliar KM, Ma W, Milton DR, Wang J, Muhlbauer A, Parra ER, Solis LM, Nagarajan P, Speiser J, Hudgens C, Cho WC, Aung PP, Patel AB, Pacha O, Nelson KC, Tetzlaff MT, Amaria RN, Torres-Cabala CA, Prieto VG, Wistuba II, Curry JL. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells. J Cutan Pathol 50(7):661-673, 2023. e-Pub 2023. PMID: 37150813.
- Brown AM, Masterson W, Lo J, Patel AB. Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review. Dermatitis 34(3):201-208, 2023. e-Pub 2023. PMID: 34405836.
- Thomas PS, Patel A, Lee JJ, Liu DD, Hernandez M, Muzzio M, Contreras A, Sepeda V, Mays C, Weber D, Vornik LA, Khan SA, Dimond E, Heckman-Stoddard BM, Perloff M, Brown PH. Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. Cancer Prev Res (Phila) 16(1):47-55, 2023. e-Pub 2023. PMID: 36228112.
- Zhu H, Narayana V, Zhou K, Patel AB. Altmetric Analysis of Dermatology Manuscript Dissemination During the COVID-19 Era: Cross Sectional Study. JMIR Dermatol 16(6):e46620, 2023. e-Pub 2023. PMID: 37585241.
- Martel J, Cho WC, Runge JS, Patel AB, Tayar J, Woodman K, Hume CB, Curry J, Heberton M. Durvalumab-associated generalized morphea with overlapping vitiligo. JAAD Case Rep 30:83-86, 2022. e-Pub 2022. PMID: 36407485.
- Bur D, Patel AB, Nelson K, Huen A, Pacha O, Phillips R, Heberton M. A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. J Am Acad Dermatol 87(6):1394-1395, 2022. e-Pub 2022. PMID: 35940366.
- Ibraheim MK, Lo J, Gupta R, Parseghian C, Patel AB. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients. Support Care Cancer 30(10):8051-8058, 2022. e-Pub 2022. PMID: 35771289.
- Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. In Reply. Oncologist 27(10):e827-e828, 2022. e-Pub 2022. PMID: 36036599.
- Ravi V, Subramaniam A, Zheng J, Amini B, Trinh VA, Joseph J, Mennel RG, Bishop AJ, Sturgis EM, Goepfert RP, Yalamanchili S, Botello G, Stephen B, Piha-Paul SA, Patel AB, Lazar AJ, Conley AP, Benjamin RS, Patel SR, Futreal PA, Somaiah N, Naing A. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer 128(18):3383-3391, 2022. e-Pub 2022. PMID: 35792683.
- Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel AB, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
- Wetzel ML, Rubin AI, Hanania H, Patel AB. Treatment recommendations for nail unit toxicities secondary to targeted cancer therapy based on collective experience and evidence-based literature review. J Am Acad Dermatol 87(1):180-183, 2022. e-Pub 2022. PMID: 34302900.
- Seervai RNH, Heberton M, Cho WC, Gill P, Murphy MB, Aung PP, Nagarajan P, Torres-Cabala CA, Patel AB, Ruiz-Bañobre J, Om A, Yamamoto T, Nikolaou V, Curry JL. Severe De Novo pustular psoriasiform immune-related adverse event associated with Nivolumab treatment for metastatic esophageal adenocarcinoma. J Cutan Pathol 49(5):472-481, 2022. e-Pub 2022. PMID: 34888886.
- Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist 27(3):e223-e232, 2022. e-Pub 2022. PMID: 35274723.
- Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 128(5):975-983, 2022. e-Pub 2022. PMID: 34724197.
- Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2022. e-Pub 2022. PMID: 34550757.
- Ibraheim MK, Gupta R, Dao H, Patel AB, Koshelev M. Evaluating skin of color education in dermatology residency programs: data from a national survey: Edited by Stephen P. Stone, MD. Clin Dermatol 40(2):228-233, 2022. e-Pub 2022. PMID: 34838657.
- Lo JJ, Heberton MM, Pacha O, Huen AO, Patel AB. Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients. Support Care Cancer 30(2):989-994, 2022. e-Pub 2022. PMID: 34519869.
- Masterson WM, Brown AM, Al Ameri MA, Patel AB. A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution. Cancer Treat Res Commun 30, 2022. e-Pub 2022. PMID: 34990901.
- Dao EA, George SJ, Heberton MM, Pacha O, Kovitz CA, Patel AB, Phillips RM. Periorbital edema associated with alpelisib. Cancer Treat Res Commun 32:100596, 2022. e-Pub 2022. PMID: 35834907.
- Dao EA, George SJ, Heberton MM, Pacha O, Kovitz CA, Patel AB, Phillips RM. Erratum to "Periorbital edema associated with alpelisib" [Cancer Treatment and Research Communications 32 (2022) 100596]. Cancer Treat Res Commun 33:100654, 2022. e-Pub 2022. PMID: 36463021.
- Karri PV, Tahseen D, Gupta R, Grant-Kels JM, Narala S, Patel AB. Can quality keep up with quantity-Longitudinal trends in research output for the dermatology residency match. Clin Dermatol 39(6):1039-1045, 2021. e-Pub 2021. PMID: 34920822.
- Robinson MA, Patel AB, Wilmas KM, Thomas V, Heberton M. Cutaneous Surgery Outcomes in Patients on Epidermal Growth Factor Receptor Inhibitors. Dermatol Surg 47(11):1519-1521, 2021. e-Pub 2021. PMID: 34417386.
- Gupta R, Ibraheim MK, Dao H, Patel AB, Koshelev M. Assessing dermatology resident confidence in caring for patients with skin of color. Clin Dermatol 39(5):873-878, 2021. e-Pub 2021. PMID: 34785015.
- Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A. Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. Cancer Discov 11(9):2158-2167, 2021. e-Pub 2021. PMID: 33910927.
- Altan M, Patel AB. Management of Cutaneous Immunotherapy Toxicities. Clin Lung Cancer 22(5):e783, 2021. e-Pub 2021. PMID: 33795210.
- Hanania HL, Pacha O, Heberton M, Patel AB. Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies. Dermatol Surg 47(6):775-779, 2021. e-Pub 2021. PMID: 34029250.
- Karri PV, Torres CA, Dailey Garnes NJ, Ronen S, Khawaja F, Bhatti MM, Hosing C, Patel AB. Disseminated atypical mycobacterial infection in an allogeneic stem cell transplant recipient. Dermatol Online J 27(6), 2021. e-Pub 2021. PMID: 34387060.
- Narala S, Li SQ, Klimas NK, Patel AB. Application of least absolute shrinkage and selection operator logistic regression for the histopathological comparison of chondrodermatitis nodularis helicis and hyperplastic actinic keratosis. J Cutan Pathol 48(6):739-744, 2021. e-Pub 2021. PMID: 33617003.
- Barrios DM, Phillips GS, Geisler AN, Trelles SR, Markova A, Noor SJ, Quigley EA, Haliasos HC, Moy AP, Schram AM, Bromberg J, Funt SA, Voss MH, Drilon A, Hellmann MD, Comen EA, Narala S, Patel AB, Wetzel M, Jung JY, Leung DYM, Lacouture ME. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 32(6):736-745, 2021. e-Pub 2021. PMID: 33667669.
- Keiser MF, Patel AB, Altan M. Cutaneous toxicities in lung cancer patients on immune checkpoint inhibitor therapy. Clin Lung Cancer 22(3):195-200.e1, 2021. e-Pub 2021. PMID: 33637416.
- McNally MA, Vangipuram R, Campbell MT, Nagarajan P, Patel AB, Curry JL, Heberton M. Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma. JAAD Case Rep 10:82-84, 2021. e-Pub 2021. PMID: 33778141.
- Karri P, Freemyer B, Aboul-Fettouh N, Patel AB, Curry JL, Rogge M. Plasma cell myeloma with immature plasma cells in the skin arising within the areas of chronic stasis dermatitis. JAAD Case Rep 7:26-29, 2021. e-Pub 2021. PMID: 33318997.
- Karri PV, Tahseen D, Patel AB. Treatment of Checkpoint Inhibitor-Induced Vitiligo in a Patient with Metastatic Renal Cell Cancer. Dermatitis 32(4):e68-e69, 2021. e-Pub 2021. PMID: 33273227.
- Krauland K, Patel AB. Junctional Melanocytic Hyperplasia Overlying Benign Fibrous Papule: An Under-recognized Variant of a Common Lesion. J Cutan Pathol 47(12):1220-1223, 2020. e-Pub 2020. PMID: 32496596.
- Karri PV, Freemyer BD, Pacha O, Patel AB. Characterization of cutaneous adverse events associated with PI3k inhibitors in 11 patients. J Immunotherapy & Precision Oncology 3(4):141-6, 2020. e-Pub 2020.
- Lee H, Jung SJ, Patel AB, Thompson JM, Qureshi A, Cho E. Racial Characteristics of Alopecia Areata in the United States. J Am Acad Dermatol 83(4):1064-1070, 2020. e-Pub 2020. PMID: 31279016.
- Messer A, Drozd B, Glitza IC, Lu H, Patel AB. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. Dermatol Online J 26(8), 2020. e-Pub 2020. PMID: 32941716.
- Welborn M, Kubicki SL, Garg N, Patel AB. Twelve cases of acneiform eruptions while on anti-CTLA4 therapy. Support Care Cancer 28(6):2499-2502, 2020. e-Pub 2020. PMID: 32147760.
- Swali R, Nwannunu C, Farooq S, Wu W, Robare S, Patel A, Tyring SK. Cutaneous myoepithelioma of the foot. Int J Dermatol 59(5):e173-e174, 2020. e-Pub 2020. PMID: 31769018.
- Andrews ED, Garg N, Patel AB. A Retrospective Chart Review on Oral Retinoids as a Treatment for Epidermal Growth Factor Receptor Inhibitor and Mitogen-activated Protein Kinase Kinase Inhibitor Induced Acneiform Eruptions. J Am Acad Dermatol 82(4):998-1000, 2020. e-Pub 2020. PMID: 31604105.
- Limmer AL, Park KE, Patel AB, Huen AO. Unusual presentation of Kaposi sarcoma in an HIV-negative woman. Dermatol Online J 26(4), 2020. e-Pub 2020. PMID: 32621687.
- Nguyen JK, Schlichte MJ, Jogi R, Alikhan M, Patel AB. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies. Dermatol Online J 26(3), 2020. e-Pub 2020. PMID: 32609446.
- Freemyer BD, Cabala TA, Patel AB. A Case Report of a Cutaneous Mucinous Reaction Associated with Erlotinib Therapy Used in the Treatment of Metastatic Tonsillar Sinus Squamous Cell Carcinoma. J Immunother Precis Oncol 3(1):31-33, 2020. e-Pub 2020. PMID: 35756178.
- Patel AB, Pacha O. Skin Reactions to Immune Checkpoint Inhibitors. Adv Exp Med Biol 1244:235-246, 2020. e-Pub 2020. PMID: 32301018.
- Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, Tetzlaff MT, Hwu P, Curry JL, Diab A. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. Cancer Immunol Res 7(6):860-865, 2019. e-Pub 2019. PMID: 30996018.
- Doan HQ, Hu MI, Goldstein J, Piha-Paul SA, Subbiah V, Patel AB. Vandetanib photoinduced cutaneous toxicities. Cutis 103(5):E24-E29, 2019. e-Pub 2019. PMID: 31233590.
- Rios A, Cen P, Dinh B, Mays SR, Patel AB. Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide. Eur J Cancer 107:97-99, 2019. e-Pub 2019. PMID: 30554075.
- Welborn M, Kubicki SL, Garg N, Patel AB. Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients. Am J Clin Dermatol 19(6):899-905, 2018. e-Pub 2018. PMID: 30073495.
- Welborn ME, Kubicki SL, Patel AB. Pyoderma gangrenosum following initiation of immune-checkpoint inhibitor therapy. J Immunother & Precision Onc 1(2):82-4, 2018. e-Pub 2018.
- Kubicki SL, Welborn ME, Patel AB. Toxic epidermal necrolysis during cotherapy with Ipilimumab and Nivolumab. J Immunother & Precision Onc 1(2):79-81, 2018. e-Pub 2018.
- Chen L, Parsons AM, Aria AB, Ciurea AM, Patel AB, Chan C, Griffin JR, Nguyen TH, Migden MR. Surgical site identification with personal digital device: A prospective pilot study. J Am Acad Dermatol 79(3):520-524, 2018. e-Pub 2018. PMID: 29524583.
- Kubicki SL, Welborn ME, Garg N, Aung PP, Patel AB. Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis). J Cutan Pathol 45(8):636-638, 2018. e-Pub 2018. PMID: 29704281.
- Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36(4):638-646, 2018. e-Pub 2018. PMID: 29159766.
- Fernandez-Flores A, Llamas-Velasco M, Saus C, Patel AB, Rutten A. Microcystic adnexal carcinoma with sebaceous differentiation: Three cases. J Cutan Pathol 45(4):290-295, 2018. e-Pub 2018. PMID: 29352496.
- Chockalingam R, Aneja S, Patel AB. Primary cutaneous follicle center lymphoma mimicking folliculitis. Cutis 101(1):E30-E33, 2018. e-Pub 2018. PMID: 29529119.
- Patel AB, Pacha O. Skin Reactions to Immune Checkpoint Inhibitors. Adv Exp Med Biol 995:117-129, 2018. e-Pub 2018. PMID: 30539508.
- Li JY, Ivan D, Patel AB. Acral retiform purpura. Lancet 390(10110):2382, 2017. e-Pub 2017. PMID: 28890159.
- Sundaresan S, Nguyen KT, Nelson KC, Ivan D, Patel AB. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab. Dermatol Online J 23(9), 2017. e-Pub 2017. PMID: 29469720.
- Patel AB, Pacha O. Skin Reactions to Immune Checkpoint Inhibitors. Adv Exp Med Biol 995:175-184, 2017. e-Pub 2017. PMID: 28321818.
- Al-Rohil RN, Torres-Cabala CA, Patel AB, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol 43(12):1161-1166, 2016. e-Pub 2016. PMID: 27531242.
- Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL. Autoimmune Dermatologic Toxicities from Immune Checkpoint Blockade with anti-PD-1 Antibody Therapy: A Report on Bullous Skin Eruptions. J Cutan Pathol 43(8):688-96, 2016. e-Pub 2016. PMID: 27086658.
- Chockalingam R, Aung P, Patel AB. Regorafenib- associated panniculitis. Dermatol Online J 22(6), 2016. e-Pub 2016. PMID: 27617607.
- Patel AB, Solomon AR, Mauro MJ, Ehst BD. Unique cutaneous reaction to second- and third- generation tyrosine kinase inhibitors for chronic myeloid leukemia. Dermatology 232(1):122-5, 2016. e-Pub 2016. PMID: 26352467.
- Patel T, Patel AB, Moody M, Kelly B, Gibson B. Tzanck smear for quick screening of transient myeloproliferative disorder in neonates with vesiculopapular eruptions. Int J Dermatol 54(7):e251-3, 2015. e-Pub 2015. PMID: 24738623.
- Goldstein J, Patel AB, Curry JL, Subbiah V, Piha-Paul S. Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. BMC Dermatol 15(1):2, 2015. e-Pub 2015. PMID: 25886034.
- Patel AB, Hill E, Simpson EL, Hanifin JM. Reversion of methicillin-resistant Staphylococcus aureus (MRSA) skin infections to methicillin-susceptible isolates. JAMA Dermatol 149(10):1167-71, 2013. e-Pub 2013. PMID: 23945667.
- Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hyperpigmentary disorders. Indian J Dermatol Venereol Leprol 79(3):367-75, 2013. e-Pub 2013. PMID: 23619441.
- Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hypopigmentary disorders. Indian J Dermatol Venereol Leprol 79(3):376-82, 2013. e-Pub 2013. PMID: 23619442.
- Leitenberger JJ, Patel AB, Cushing MC, Jack AR. Resident Rounds: Part II Contact allergens relevant to dermatitis in special locations. J Drugs Dermatol 11(5):657-8, 2012. e-Pub 2012.
- Patel AB, Wagle RR, Usrey MM, Thompson MT, Incavo SJ, Noble PC. Guidelines for implant placement to minimize impingement during activities of daily living after total hip arthroplasty. J Arthroplasty 25(8):1275-81.e1, 2010. e-Pub 2010. PMID: 20022449.
- Patel AB, Rosen T. Herpes vegetans as a sign of HIV infection. Dermatol Online J 14(4):6, 2008. e-Pub 2008. PMID: 18627728.
- Patel AB, Harting MS, Hsu S. Solid facial edema: treatment failure with oral isotretinoin monotherapy and combination oral isotretinoin and oral steroid therapy. Dermatol Online J 14(1):14, 2008. e-Pub 2008. PMID: 18319031.
- Patel AB, Harting MS, Smith-Zagone MJ, Hsu S. Familial basaloid follicular hamartoma: a report of one family. Dermatol Online J 14(4):14, 2008. e-Pub 2008. PMID: 18627736.
Invited Articles
- Patel AB, Lacouture ME. Mucocutaneous toxicities with immune checkpoint inhibitors. Up to Date Online, 2021. e-Pub 2021.
Review Articles
- Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15:1447021, 2024. e-Pub 2024. PMID: 39247203.
- Iriarte C, Yeh JE, Alloo A, Boull C, Carlberg VM, Coughlin CC, Lara-Corrales I, Levy R, Nguyen CV, Oza VS, Patel AB, Rotemberg V, Shah SD, Zheng L, Miller CH, Hlobik M, Daigneault J, Choi JN, Huang JT, Vivar KL. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature. Support Care Cancer 32(9):610, 2024. e-Pub 2024. PMID: 39174797.
- Martel J, Hanania HL, Patel AB. Immune checkpoint inhibitor-induced cutaneous toxicities: A review of histopathologic and clinical features. Hum Pathol 140:144-172, 2023. e-Pub 2023. PMID: 37141978.
- Muhaj F, Karri PV, Moody W, Brown A, Patel AB. Mucocutaneous adverse events to immune checkpoint inhibitors. Front Allergy 4:1147513, 2023. e-Pub 2023. PMID: 36938327.
- Cabanillas ME, Patel AB, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF inhibitors in thyroid cancer: a review of efficacy and toxicity beyond melanoma. Horm Cancer 6(1):21-36, 2015. e-Pub 2015. PMID: 25467940.
- Patel AB. Post inflammatory hyperpigmentation: Review of pathogenesis, prevention, and treatment. Pigment International 1(2):59-69, 2015. e-Pub 2015.
- Patel AB, Katta R. Allergen Profile: Neomycin. Dermatitis 19(2):E7-8, 2008. e-Pub 2008. PMID: 18413103.
Abstracts
- Simbaqueba Clavijo C, Altan M, Franco Vega M, Palaskas N, Gupta R, Rivera M, Patel AB. Cemiplimab safety in patients with advanced cutaneous CSCC and non-small cell lung cancer NSCLSC. The MD Anderson experience. MASCC/JASCC/ISOO 2023 Annual Meeting Japan, 2023. e-Pub 2023.
- Patel A, Anadkat MJ, Marathe O, Webb ML, Tyler RC, Zhang W, Wu C, Ju J, Tang H, Luo J, Lacouture ME. NOVA-II: Part 2 study to evaluate the safety and efficacy of OQL011 on VEGF inhibitor-associated hand-foot skin reaction in patients with cancer. 2023 ASCO Genitourinary Cancers Symposium, 2023. e-Pub 2023.
- Hannah HL, Wetzel ML, Rubin AI, Patel AB. Anticancer Therapy-Induced Nail Toxicity: Review of The Literature and Management Recommendations. MASCC/ISOO 2022 Annual Meeting : June 2022, Toronto, ON, 2022. e-Pub 2022.
- Lacouture ME, Anadkat MJ, Patel AB, Marathe OS, Webb ML, Tyler RC, Chen L, Wu C, Li W, Ju J, Luo J, Tang H, Vogelzang NJ. A survey study of prevention and treatment patterns by academic and community oncologists for papulopustular, acneiform skin rash associated with epidermal growth factor receptor inhibitor (EGFRi) therapy. 2022 ASCO Annual Meeting (June 3 - June 7, 2022), 2022. e-Pub 2022.
- McNally M, Patel AB, Thomas V, Heberton M. Oral abstract: Cutaneous surgery outcomes in patients on EGFR inhibitors. AAD VMX meeting, 2021. e-Pub 2021.
- Marques-Piubelli ML, Tetzlaff MT, Mudaliar KM, Muhlbauer A, Ma W, Wang J, Chon S, Nelson K, Nagarajan P, Aung P, Torres-Cabala C, Patel AB, Pacha O, Amaria RN, Prieto VG, Subramanya S, Wistuba II, Curry JL. Differentially expressed genes in bullous pemphigoid immune-related adverse event (BP-irAE) from immune checkpoint inhibitor therapy: Implications in the immunopathogenic mechanisms driving BP-irAE compared to de novo BP control. Annual Meeting, United States and Canadian Academy of Pathology, Los Angeles, CA Feb 29-Mar 5, 2020, 2019. e-Pub 2019.
- Ketcham M, Freemyer B, Torres-Cabala CA, Patel AB. Erlotinib-related eruptive cutaneous mucinosis. Amer Soc of Dermatopathology Annual Meeting Oct 2017, 2017. e-Pub 2017.
- Kubicki S, Welborn M, Patel AB. Poster: Granulomatous dermatitis induced by ipilimumab. American Academy of Dermatology Annual Meeting, Orlando, FL March 2017, 2017. e-Pub 2017.
- Rogge M, Patel AB. Poster: Impact of cutaneous toxicities in patients taking Vandetanib. American Academy of Dermatology Annual Meeting, Orlando, FL March 2017, 2017. e-Pub 2017.
- Welborn M, Kubicki S, Patel AB. Poster: Cutaneous adverse events in tremelimumab, a 2nd generation anti-CTLA4 inhibitor. American Academy of Dermatology Annual Meeting, Orlando, FL March 2017, 2017. e-Pub 2017.
- Mian I, Yang M, Zhao H, Shah M, Diab A, Shannon V, Patel AB, Amaria R, Giordano S, Suarez-Almozar M. Poster: Immune related adverse events associated with Ipilimumab. Am Soc of Clin Onc Annual mtg, Chicago, IL June 2016, 2016. e-Pub 2016.
- Zahiruddin SH, Aung P, Patel AB. Poster: Loss of CD30+ expression after treatment with Brentuximab Vedotin (BV) in a patient with anaplastic large cell lymphoma: a new phenomenon. Am Acad Derm annual mtg Washington DC March 2016, 2016. e-Pub 2016.
- Zahiruddin SH, Aung P, Patel AB. Loss of CD30+ expression after treatment with Brentuximab Vedotin (BV) in a patient with anaplastic large cell lymphoma: a new phenomenon. Gross and Microscopic Seminar, Amer Acad of Derm Annual meeting Washington DC March 2016, 2016. e-Pub 2016.
- Kim SR, Chen L, Hebert AA, Slopis J, Koenig MK, Patel AB. Poster: Erythema nodosum in the setting of Everolimus use. Am Acad Derm annual mtg Washington DC March 2016, 2016. e-Pub 2016.
- Nguyen AV, Ellis RM, Hebert AA, Cabala-Torres CA, Patel AB. Poster: Diffuse papulonodules: a rare presentation of leukemia cutis. Am Acad Derm annual Mtg, Washington, DC March 2016, 2016. e-Pub 2016.
- Al-Rohil R, Patel AB, Miranda R, Medeiros J, Prieto V, Torres-Cabala C, Aung P. A new finding of loss of CD30+ expression after treatment with Brentuximab in a patient with anaplastic large cell lymphoma. American Society of Dermatopathology Annual Meeting San Francisco Oct 2015, 2015. e-Pub 2015.
- Aneja S, Chockalingam R, Young KH, Patel AB. Poster: Cutaneous follicle center lymphoma mimicking folliculitis. Texas Dermatology Society Spring Meeting, Austin, TX May 2015, 2015. e-Pub 2015.
- Patel AB, Mauro M, Solomon A, Ehst BD. Poster: Unique cutaneous reaction to second- and third- generation tyrosine kinase inhibitors for chronic myeloid leukemia. Society of Investigative Dermatology Atlanta GA May 2015, 2015. e-Pub 2015.
- Quinn AM, Kim SR, Patel AB, Wagle RR, Usrey MM, Thompson MT, Mathis KB. Poster: Everolimus-induced erythema nodosum. TX Derm Soc Annual meeting Bastrop TX Oct 2014, 2014. e-Pub 2014.
- Sweeney SA, Miranda R, Hymes SR, Patel AB. Extensive oral erosions in a patient with CLL. TX Derm Soc Annual Meeting Bastrop TX, 2014. e-Pub 2014.
- Goodwin B, Sedrak M, Patel AB, Sanchez RL. Poster: Atypical fibroxanthoma with osteoid formation: a rare variant. 50th American Society of Dermatopathology annual meeting Washington, DC Oct 2013 41(2), 2013. e-Pub 2013.
- Jensen A, Patel AB, White CR. Poster: A case of a Spitz's nevus in a patient with BRCA2 mutation. 49th American Society of Dermatopathology Annual Meeting, Chicago, IL Oct 2012, 2012. e-Pub 2012.
- Patel AB, Chandler H, Thompson CT. Poster: Sebopsoriasis: An uncommon diagnosis with unique histologic features. 49th American Society of Dermatopathology Annual Meeting, Chicago, IL Oct 2012, 2012. e-Pub 2012.
- Patel AB, Hill E, Simpson EL, Hanifin JM. Poster: Do patients with methicillin-resistant Staphyloccus aureus (MRSA) infections of the skin revert to methicillin-susceptible isolates?. Society of Investigative Dermatology Annual Meeting, Raleigh, NC May 2012, 2012. e-Pub 2012.
- Patel AB, Solomon AR. Poster: Double jeopardy- cutaneous B-cell lymphoma mimicking CTCL and presenting as delusions of parasitosis. International Society of Dermatopathology Pre-AAD meeting, San Diego, CA Feb 2012, 2012. e-Pub 2012.
- Patel AB, White CR. Granulomatous mycosis fungoides masquerading as central facial granulomas. 48th American Society of Dermatopathology Annual Meeting, Seattle, WA Oct 2011, 2011. e-Pub 2011.
- Patel AB, White KP, Ehst BE, White CR. Persistent pruritic pustules: A classic presentation of rare disease. 47th American Society of Dermatopathology Annual Meeting, Atlanta, GA Oct 2010, 2010. e-Pub 2010.
- Wagle RR, Noble PC, Patel AB, Thompson MT. Which intraoperative maneuvers predict acceptable hip motion after total hip replacement?. Scientific Symposium: Science & Techniques of Adult Joint Reconstruction, Plus Education Institute, Gold Coast, Australia, 2007. e-Pub 2007.
- Noble PC, Usrey MM, Patel AB, Wagle RR, Thompson MT, Mathis KB. Restoring normal hip motion: implant design factors. Scientific Symposium: Tribology in Orthopedic Surgery, Florence, 2007. e-Pub 2007.
- Patel AB, Wagle RR, Thompson MT, Mathis KB, Noble, PC. Poster: Rules of thumb for predicting risks of prosthetic and bony impingement after total hip replacement. Annual Meeting of the Orthopedic Research Society, Chicago, IL March 2006, 2006. e-Pub 2006.
- Wagle RR, Patel AB, Thompson MT, Noble PC. Poster: Which intraoperative maneuvers accurately predict adequate joint motion for functional activities after total hip replacement?. Annual Meeting of the American Academy of Orthopedic Surgeons, Chicago, IL March 2006, 2006. e-Pub 2006.
- Wagle RR, Patel AB, Thompson MT, Noble PC. Poster: Which intraoperative maneuvers accurately predict adequate joint motion for functional activities after total hip replacement?. Annual Meeting of the Orthopedic Research Society, Chicago, IL March 2006, 2006. e-Pub 2006.
- Noble PC, Patel AB, Wagle RR, Usrey MM, Thompson MT, Mathis KB. Prosthetic and bony impingement after THR: Guidelines from computer simulations, PC Noble. Scientific Symposium on Reconstruction of the Diseased Hip, Bern, Switzerland, 2006. e-Pub 2006.
- Wagle RR, Patel AB, Thompson MT, Noble PC. Poster: Which intraoperative maneuvers accurately predict adequate joint motion for functional activities after total hip replacement?. James K Alexander Research Symposium, Baylor College of Medicine, Houston, TX 2006, 2006. e-Pub 2006.
- Patel AB, Wagle RR, Thompson MT, Mathis KB, Noble PC. Poster: Rules of thumb for predicting risks of prosthetic and bony impingement after total hip replacement. James K Alexander Research Symposium, Baylor College of Medicine, Houston, TX 2006, 2006. e-Pub 2006.
- Patel AB, Osmond JK. Poster: New method of plutonium detection in nuclear geochemistry. Inter'l Science and Engineering Fair 1998, 1998. e-Pub 1998.
- Patel AB, Osmond JK. Poster: New method of plutonium detection in nuclear geochemistry. NSF / YSP conference 1997, 1997. e-Pub 1997.
Book Chapters
- Lohray R, Patel AB. Chapter 4: Dermatomyositis Post Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, 33-42, 2025.
- Wang HY, Aung P, Patel AB. Chapter 2: Bullous Pemphigoid Post Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, 11-20, 2025.
- Wang HY, Torres-Cabala CA, Patel AB. Chapter 3: Erosive Oral Lichen Planus with Pemphigus Vulgaris Post Immune Checkpoint Inhibitor Treatment. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, 21-32, 2025.
- Gupta R, Patel AB. Chapter 8: Bullous Reactions. In: In: Cutaneous Reactions to Anti-Cancer Therapies. 1st, 2023.
- Patel AB, Duvic M. Chapter 125: Dermatologic Complications of Cancer Chemotherapy. In: Holland-Frei Cancer Medicine. 10, 2022.
- Brown AM, Masterson W, Patel AB. Skin Toxicities. In: In: Managing Immunotherapy Related Organ Toxicities: A Practical Guide. 1st, 2022.
- Patel AB, Pacha P. Chapter 5: Skin Reactions to Immune Checkpoint Inhibitors. In: Immunotherapy. 4, 2022.
- Patel, AB, Pacha, O. Skin Reactions to Immune Checkpoint Inhibitors, 319-330, 2021.
- Patel AB, Pacha P. Chapter 5: Skin reactions to immune checkpoint inhibitors. In: IN: Immunotherapy. 3rd, 2020.
- Patel AB, Pacha P. Chapter 5: Skin reactions to immune checkpoint inhibitors. In: IN: Immunotherapy. 2nd, 2018.
- Patel AB, Pacha P. Chapter 5: Skin reactions to immune checkpoint inhibitors. In: IN: Immunotherapy. 1st, 2017.
- Patel AB, Duvic M. Chapter 125: Dermatologic Complications of Cancer Chemotherapy. In: Holland-Frei Cancer Medicine. 9th, 2017.
- Devere TS, Patel AB. Chapter 165: Pigmented Purpuric Dermatoses. In: Fitzpatrick's Dermatology in General Medicine. 8th, 2012.
Patient Reviews
CV information above last modified March 10, 2026